Age-Appropriate Advance Care Planning in Children Diagnosed with a Life-Limiting Condition: A Systematic Review

Julie Brunetta 1, Jurrianne Fahner 2,*, Monique Legemaat 3, Esther van den Bergh 3, Koen Krommenhoek 3, Kyra Prinsze 3, Marijke Kars 1 and Erna Michiels 3

1 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands; j.brunetta@students.uu.nl (J.B.); m.c.kars@umcutrecht.nl (M.K.)
2 Division of Pediatrics, Wilhelmina Children’s Hospital, 3584 EA Utrecht, The Netherlands
3 Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands; m.m.legemaat@prinsesmaximacentrum.nl (M.L.); e.m.m.vandenbergh@prinsesmaximacentrum.nl (E.v.d.B.); k.b.krommenhoek@students.uu.nl (K.K.); k.j.prinsze2@students.uu.nl (K.P.); e.michiels@prinsesmaximacentrum.nl (E.M.)

* Correspondence: j.c.fahner@umcutrecht.nl

Abstract: Pediatric advance care planning (pACP) is an important strategy to support patient-centered care. It is known to be difficult, yet paramount, to involve the child in pACP while adjusting treatment to age and the corresponding stage of development. This systematic review was aimed to evaluate the age appropriateness of pACP interventions by assessing their characteristics, content, and evidence. CINAHL, Embase and MEDLINE were searched from 1 January 1998 to 31 August 2020 in order to identify peer-reviewed articles containing strategies and tools to facilitate pACP in both children (0–18 years) with life-limiting conditions and their families. An assessment of quality was performed using Cochrane tools and COREQ. The full protocol is available as PROSPERO CRD42020152243. Thirty-one articles describing 18 unique pACP tools were included. Most tools were developed for adolescents and young adults. In most cases, the interventions tried to assess the child’s and family’s preferences concerning their current and future hopes, wishes, and goals of the care. This was aimed to enhance communication about these preferences between children, their families, and health-care providers and to improve engagement in pACP. The relevance of an age-appropriate approach was mentioned in most articles, but this was mainly implicit. Seven articles implemented age-appropriate elements. Six factors influencing age appropriateness were identified. Tools to support pACP integrated age-appropriate elements to a very limited extent. They mainly focused on adolescents. The involvement of children of all ages may need a more comprehensive approach.

Keywords: palliative care; life-limiting conditions; pediatrics; adolescents; advance care planning; age-appropriate; development; cognitive functions; young adults; interventions

1. Introduction

Children with life-limiting conditions often receive highly complex care over a long period of time. This care may include high-risk treatments with severe side effects and palliative care services. The medical conditions and care needs of these children often interfere with their daily life, including their social activities [1]. These children live with the burden of invasive treatment procedures, hospital admissions, and (often) side-effects from therapies [2,3]. However, these children are not routinely asked about their experiences regarding living with illness [3]. In addition, the child’s voice is not systematically included in decision making or when discussing treatment preferences [3]. The involvement of parents and children, in a way appropriate for both age and level of development [4], in decision making is considered obligatory in family-centered health care. However, involving children and families is challenging in practice. Uncertainty about prognoses,
fears of disrupting coping strategies, intercultural differences, and the changing demands of developing children make clinicians feel reluctant to initiate conversations about future care with children and their families [5–7]. Furthermore, tools to support the participation of children in decision making regarding their own health care are scarce. However, these tools are needed if the child’s perspective when discussing goals and preferences for care and treatment is to be included [8]. In the literature, reports of pediatric advance care planning (pACP) interventions are increasing [9–13]. They are intended to connect the expertise of the child and family with that of the medical team in order to define the shared goals of their care and to better communicate these to all caregivers involved in the child’s treatment [14–16]. Advance care planning includes considering the voice of the child, either by listening to the child itself or by identifying the child’s perspective through the parents or other involved caregivers. An age-appropriate approach is needed to identify the child’s perspective in an adequate way. The child’s age, with their corresponding cognitive development, will influence their ability to participate in conversations [4]. The development age of children was divided by Piaget into four stages based on the level of development adequate for the calendar age. These stages are: the sensorimotor stage (from zero to two years old), the pre-operational stage (from two to seven years old), the concrete operational stage (from seven to 11 years old), and the formal operation stage (12 years and above) [5,17]. These stages were based on the idea that different age groups correspond with different levels of cognitive development. However, due to multiple factors, including illness, development age can differ from calendar age. We refer to age appropriateness for a certain development age. Clinicians experience difficulties in incorporating age-appropriate communication strategies tailored to individual needs of children [5]. Even when a child is not too young or cognitively impaired and is able to participate in a conversation, clinicians still tend to focus on the parents when discussing the child’s illness [18]. While parents will act as advocates for their child’s health, their needs, interests, and coping strategies may interfere with the child’s perspective and best interests. This limits the parents’ ability to discuss or represent the voice of their child, particularly during the palliative phase [19,20]. Although the outcomes of pACP interventions are promising, it is unknown to what extent interventions elicit the voice of the child in a manner appropriate to their age. The adequate participation of children in ACP can therefore be achieved by using strategies that consider the development ages of children. An overview of pACP interventions appropriate to different ages would be helpful in order to gain insight into strategies for adequately involving children with life-limiting conditions in their own health-care decisions. To our knowledge, an overview of such pACP interventions is still lacking. Therefore, this review was aimed to identify if and how pACP interventions incorporate elements appropriate to the child’s age.

2. Materials and Methods

2.1. Data Sources and Searches

This review was structured using The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist and the Palliative Care Literature Review Iterative Method (PALETTE) [21,22]. A structured computerized literature search was conducted in three databases: CINAHL, Embase, and MEDLINE. The search strategy was developed in collaboration with an information specialist and included terms describing the following domains: advance care planning, critical illness, and pediatrics (Table 1). These terms were searched for in all fields, with synonyms and truncations added. Three reviewers independently screened all abstracts in order to select papers reporting on pACP tools in children (0–18 years old) with life-limiting conditions [23]. We resolved questions about whether to include some papers through discussion. The reference lists of studies we included were hand-searched for additional relevant articles.
Table 1. Search string for Medline. Search date: 31 August 2020.

| Search string for Medline. Search date: 31 August 2020. |
|------------------------------------------------------|
| (critical illness[MeSH Terms] OR critical illness*[tiab] OR 'critically ill'[tiab] OR life limiting condition*[tiab] OR life-limiting disease*[tiab] OR life threatening illness*[tiab] OR life threatening condition*[tiab] OR serious illness*[tiab] OR palliative care[MeSH] OR terminal care[MeSH] OR 'palliative care'[tiab] OR 'palliative medicine'[tiab] OR 'palliative nursing'[tiab] OR 'palliative period'[tiab] OR 'palliative phase'[tiab] OR 'palliative therapy'[tiab] OR palliative treatment*[tiab] OR 'palliative supportive care'[tiab] OR 'terminal care'[tiab] OR 'terminal medicine'[tiab] OR 'terminal period'[tiab] OR 'terminal phase'[tiab] OR EOL[tiab] OR end of life*[tiab]) |
| **And** |
| ('advance care planning'[MeSH] OR 'advance directives'[MeSH] OR 'decision making'[MeSH] OR 'living wills'[MeSH] OR 'patient participation'[MeSH] OR advance care plan*[tiab] OR ACP*[tiab] OR pACP*[tiab] OR advance decision*[tiab] OR advance directive*[tiab] OR advance medical directive*[tiab] OR advance healthcare planning*[tiab] OR advance medical planning*[tiab] OR advance statement*[tiab] OR 'do not hospitalize'[tiab] OR 'do not hospitalise'[tiab] OR 'do not resuscitate'[tiab] OR 'do not attempt cardiopulmonary resuscitation'[tiab] OR 'DNR order'[tiab] OR DNACPR*[tiab] OR 'planning ahead'[tiab] OR 'refusal of treatment'[tiab] OR treatment limitation*[tiab] OR guide*[tiab] OR program*[tiab] OR procedure*[tiab] OR practice*[tiab] OR treatment limiting*[tiab] OR shared decision*[tiab] OR 'patient participation'[tiab] OR 'patient involvement'[tiab] OR 'child centered care'[tiab] OR 'person centered care'[tiab] OR 'patient centered care'[tiab]) |
| **And** |
| (Infant*[tiab] OR toddler*[tiab] OR minor*[tiab] OR minors*[tiab] OR boy*[tiab] OR boys*[tiab] OR boyfriend*[tiab] OR boyfriends*[tiab] OR boyhood*[tiab] OR girl*[tiab] OR girls*[tiab] OR girlfriend*[tiab] OR girlfriends*[tiab] OR kid*[tiab] OR kids*[tiab] OR child*[tiab] OR children*[tiab] OR schoolchild*[tiab] OR school child*[tiab] OR adolescence*[tiab] OR adolescence*[tiab] OR youth*[tiab] OR teen*[tiab] OR under age*[tiab] OR pubescence*[tiab] OR puberty*[tiab] OR pediatrics[MeSH] OR pediatric*[tiab] OR paediatrics*[tiab] OR school*[tiab] OR school*[tiab] OR prematurity*[tiab] OR preterm*[tiab] OR youth*[tiab] OR boys*[tiab] OR teen*[tiab] OR teens*[tiab] OR teenager*[tiab] OR younger*[tiab] OR child*[MeSH] OR neonate*[tiab] OR baby*[tiab] OR babies*[tiab] OR toddler*[tiab] OR newborn*[tiab] OR postneonate*[tiab] OR postnat*[tiab] OR perinatal*[tiab] OR preschool*[tiab] OR suckling*[tiab] OR picu*[tiab] OR nicu*[tiab] OR neo-nat*[tiab] OR neonate*[tiab] OR prematurity*[tiab] OR postmaturity*[tiab] OR pre-maturity*[tiab] OR preterm*[tiab] OR pre-term*[tiab] OR playgroup*[tiab] OR play-group*[tiab] OR playschool*[tiab] OR preschool*[tiab] OR prepubescent*[tiab] OR preadolescent*[tiab] OR junior high*[tiab] OR highschool*[tiab] OR senior high*[tiab] OR young people*[tiab]) |

| **Truncations were added.** |

2.2. Study Selection

Articles published in English in peer-reviewed journals between 1 January 1998 and 31 August 2020 were eligible for inclusion if they reported on a well-described strategy or tool for supporting pACP. pACP was defined as a strategy to identify preferences and goals for future care and treatment [24] by connecting the expertise of the child and family with the expertise of the medical team [14–16]. Exclusion criteria were systematic reviews, articles published before 1998, and articles reporting on prenatal advance care planning. The full texts of potentially eligible studies were independently assessed by three reviewers. Disagreements were resolved in discussion with members of the research team. If an article did not provide a comprehensive description of the tool, then more detailed information was requested from the first author by email.

2.3. Data Extraction and Quality Assessment

Data extraction was conducted by two authors using a predesigned form [25]. Data regarding the content of the tool, the person conducting the conversation about ACP, its target population, and the items and outcomes related to age appropriateness were extracted. Two authors independently evaluated the studies’ methodological rigor by using the appropriate tool. Disagreements were resolved through discussion. We used the Cochrane Collaboration’s risk of bias tool for randomized controlled trials [26]. This
enabled us to evaluate the following: random sequence generation, allocation concealment, the blinding of participants, the blinding of outcome assessments, incomplete outcome data, and selective reporting. One or zero points were allocated when there was a low or high bias risk, respectively. An unclear risk of bias was noted with a question mark, resulting in zero points. A total score of six was achievable. Observational studies were evaluated with an adapted version of the Cochrane bias tool. This enabled us to appraise the selection of study population, the comparability of study groups, the standardization of intervention protocols, the standardization of outcome measurements, any missing data, any confounders, and any selective outcome reporting [26]. Points were assigned as mentioned above. A total score ranging from zero to seven was counted. Qualitative studies were evaluated using the COmprehensive consolidated criteria for REporting Qualitative research (COREQ), assessing 32 criteria concerning three domains: the research team and reflexivity, the study design, and the analysis and findings [27]. Scores of one, 0.5, and zero points were assigned when the score was, respectively, properly described in the manuscript, incomplete, and not described. Assessments of both the risk of bias and the quality of reporting were conducted for mixed-method study designs. A few articles were not critically appraised due to their narrative, non-empirical study design. This review was exploratory in nature, so inclusion was not affected by the quality of selected papers [28].

2.4. Data Synthesis and Analysis

The researchers listed the characteristics and content of the pACP tools and their reported empirical outcomes. A narrative synthesis was provided to summarize the results [29]. Any age-appropriate elements and related theoretical groundings were identified by using a qualitative approach. Age-appropriate elements were defined as components of the tool that were adapted to a specific age and corresponding stage of cognitive development. It was reported whether elements were adapted on the basis of age groups in general or, specifically, on the development capacities that matched a specific stage of development. Fragments of articles related to age appropriateness were extracted. The open coding of these fragments resulted in a list of codes related to age appropriateness. Overarching concepts that describe factors influencing age appropriateness in the context of pACP were identified [30]. The protocol of this review is registered in the public registry PROSPERO, with registration number CRD42020152243.

3. Results

The search identified 11,685 unique hits, resulting in 62 articles eligible for full-text screening. Thirty-four articles were excluded after full-text screening. Twenty-seven had no description of a pACP tool, one article reported on adults, and six articles were excluded based on their study design (systematic review, prenatal pACP or published before 1998). Thirty-one articles, reporting on 18 unique pACP tools, met the inclusion criteria (Figure 1). Twenty-one articles were original empirical studies reporting outcome data, including six trials [31–36], six observational studies [37–42], four qualitative studies [11,43–45], and five studies that used mixed methods (observational and qualitative study design) [46–50]. Ten articles described a tool or intervention without reporting any empirical data [51–60]. Most studies (n = 24) were conducted and published in the USA [31–43,46–49,51–53,56,58–60], five were published and conducted in the UK [44,45,50,54,55], one was published and conducted in the Netherlands [11], and one was published and conducted in Canada [57].
3.1. Risk of Bias and Quality of Reporting

Tables A1–A3 of Appendix A show an overview of the scores per article, with regard to the risk of bias and an assessment of the quality of reporting. The total scores per study are presented below (Tables 2–6: Article Characteristics). The six randomized controlled trials had a median total score of 4 out of 6 (range: 3–5). All six articles could not blind their participants and therefore did not meet this criterion. For observational studies (n = 6) and the quantitative parts of mixed-method studies (n = 5), the median scores were 3 (range: 2–5) and 4 (range: 2–5), respectively. The qualitative studies (n = 4) had a median total score of 10 out of 32 (range: 4–18). For mixed-method studies (n = 5), the median total score of the qualitative part was 8.5 (range: 4.5–12).

Table 2. Evidence from randomized controlled trials.

| Author, Year, Country | Aim | Population (Age in Years), n | Outcome Parameters | Risk of Bias Total Score (6) |
|-----------------------|-----|-----------------------------|-------------------|-----------------------------|
| Dallas, 2016, USA [31] | FACE (Familial/Adolescent-Centered Advance Care Planning) vs. Healthy Living Control Condition | Adolescents with HIV (14–21) and their family decision maker, dyads n = 97 (I: 48, C: 49) | FACE: 1. Participant enrollment and attendance 2. Satisfaction based on positive and negative experienced emotions (Satisfaction Questionnaire) 3. Serious adverse event | 5 |
| Lyon, 2009, USA [32]  | FACE vs. Healthy Living Control Condition | Adolescents with HIV/AIDS (14–21) and surrogate, dyads n = 38 (I: 20, C: 18) | FACE: 1. Participant enrollment, attendance, and retention 2. Data completeness 3. Satisfaction based on positive and negative experienced emotions (Satisfaction Questionnaire) | 3 |
| Lyon, 2009, USA [33]  | FACE vs. Healthy Living Control Condition | Adolescents with HIV/AIDS (14–21) and surrogate, dyads n = 38 (I: 18, C: 17) | FACE: 1. Family congruence 2. Adolescent decisional conflict 3. Quality of communication | 3 |
### Table 2. Cont.

| Author, Year, Country * | Aim | Population (Age in Years), n | Outcome Parameters | Risk of Bias Total Score (6) |
|-------------------------|-----|-----------------------------|--------------------|------------------------------|
| Lyon, 2010, USA [34]   | FACE vs. Healthy Living Control Condition | Adolescents with HIV (14–21) and legal guardian, dyads n = 38 (I: 18, C: 17) | FACE: 1. Data completeness 2. Psychological effects (based on anxiety and depression scales) 4. Physical effects on HIV symptoms | 4 |
| Lyon, 2013, USA [35]   | FACE vs. Treatment as Usual | Adolescent with cancer (14–21) and their Surrogate, dyads n = 30 (I: 17, C: 13) | FACE: 1. Family congruence 2. Adolescents decisional conflict 3. Quality of communication | 3 |
| Lyon, 2014, USA [36]   | FACE vs. Treatment as Usual | Adolescent with cancer (14–21) and their Surrogate, dyads n = 30 (I: 17, C: 13) | FACE-TC (Family/Adolescent-Centered Advance Care Planning for Teens with Cancer): 1. Satisfaction based on positive and negative experienced emotions (Satisfaction Questionnaire) 2. Quality of life 3. Emotional effects based on anxiety and depression scales 4. Spiritual well-being 5. Participant enrollment, attendance, and retention 6. Data completeness | 4 |

AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus; * Country where study was conducted.

### Table 3. Evidence from observational studies.

| Author, Year, Country * | Aim (A), Design (D) | Population (Age in Years), n | Outcomes | Risk of Bias Total Score (6) |
|-------------------------|--------------------|-----------------------------|-----------|------------------------------|
| Friebert, 2020, USA [42] | A: To assess adolescents’ EOL needs and family congruence D: Survey study from intervention arm FACE-TC (Family/Adolescent-Centered Advance Care Planning for Teens with Cancer) (session 1) RCT | Adolescents with cancer (14–21) and their legal or chosen guardian, dyads n = 80 | FACE-TC: 1. Adolescent’s EOL values and needs 2. Family congruence | 6 |
| Hays, 2006, USA [37]    | A: To assess the effects of DMT (Decision-Making Tool) on family satisfaction and QOL non-experimental pre-test and post-test D: Nonexperimental pre-test, post-test comparison study | Children and adolescents with potentially life-limiting illness (0–22) and their parents, dyads n = 41 | DMT: 1. Effects on quality of life on four domains (physical, emotional, social, and school functioning) 2. Family satisfaction | 4 |
| Hendricks, 2017, USA [38] | A: To evaluate COMPLETE (Communication Plan: Early through End of Life intervention) on the parent and provider levels and to describe the given parental responses. D: Prospective, longitudinal, single-group pilot study | Parents of children (0–18) with a brain tumor and a poor prognosis, mostly mothers; parents n = 13 and children n = 11 | COMPLETE: 1. Parents: emotional well-being (needs, hopes, decision regret, resources, distress, and uncertainty), satisfaction with provider communication and symptom management, and perception of information provided 2. Provider: satisfaction and communication competence | 5 |
### Table 3. Cont.

| Author, Year, Country * | Aim (A), Design (D) | Population (Age in Years), n | Outcomes | Risk of Bias Total Score (6) |
|-------------------------|---------------------|-------------------------------|----------|----------------------------|
| Jacobs, 2015, USA [39]  | A: To examine EOL family congruence  
D: Survey study from intervention arm RCT provider post-hoc survey | Adolescents with cancer (14–21) and their legal or chosen guardian, dyads n = 17 and clinicians n = 30 | FACE-TC:  
1. Adolescent’s EOL preferences  
2. Family congruence  
3. Provider survey on three sections: career, FACE-TC interactions, and EOL care experiences | 5 |
| Kazmerski, 2016, USA [40] | A: To assess patient and provider attitudes and preferences towards VMC (Voicing My Choices)  
D: Pre–post-test training survey quality improvement study | Patients with advanced CF (≤22); patients n = 12, providers (pre-training) n = 6, and providers (post-training) n = 7 | Patient and provider (pre- and post-training):  
1. ACP: positive and negative associations, preferences in CF care  
2. VMC: thoughts on VMC and age appropriateness | 2 |
| Moody, 2020, USA [41]  | A: To assess effects of COMPLETE on EOL outcomes  
D: Two-phase, single-arm, two-center prospective pre–post-intervention pilot study | Phase I: Parents of children with newly diagnosed cancer (1–<18 months), parents n = 21 and children n = 18  
Phase II: Parents of children with any prognosis, parents n = 20 and children n = 17 | COMPLETE:  
1. Parent and child: time of hospice enrollment, pain, EOL interventions, and location of death  
2. Parent: negative emotions | 4 |

ACP: advance care planning; CF: cystic fibrosis; EOL: end of life; QOL: quality of life; RCT: randomized controlled trial; * Country where study was conducted.

### Table 4. Evidence from mixed-method studies.

| Author, Year, Country * | Aim (A), Design (D) | Population (Age in Years), n | Outcome Parameters | Risk of Bias Total Score (6) | Quality of Reporting Total Score (32) |
|-------------------------|---------------------|-------------------------------|-------------------|-----------------------------|-------------------------------------|
| Kline, 2012, USA [46]   | A: To assess family satisfaction and preferences with their palliative care program and its DMT tool (Decision-Making Tool)  
D: Supportive care survey and open-ended questions interview study | Guardians of high-risk hemato-oncology pediatric patients (mean of 9.7), n = 20 (quantitative outcomes) and n = 6 (qualitative outcomes) | 1. Understanding treatment options  
2. Factors, people and services guiding treatment decisions  
3. Effectiveness of the decision-making conference, the palliative care program and DMT | 4 | 6 |
| Lyon, 2019, USA [47]    | A: To assess the feasibility and acceptability of FACE-Rare (FAmily-CEntered pediatric Advance Care Planning-Rare)  
D: Pre–post-test questionnaire study | Pediatric patients with rare diseases (≥1–≤21) and their legal guardians or family caregivers (all mothers), dyads n = 6 | FACE-Rare  
1. Caregiver appraisal  
2. Family satisfaction based on positive and negative experienced emotions  
3. Families’ quality of communication with providers | 5 | 8.5 |
Table 4. Cont.

| Author, Year, Country * | Aim (A), Design (D) | Population (Age in Years), n | Outcome Parameters | Risk of Bias Total Score (6) | Quality of Reporting Total Score (32) |
|-------------------------|---------------------|------------------------------|--------------------|-----------------------------|--------------------------------------|
| Noyes, 2013, UK [50]    | A: To evaluate ‘My Choices’ and enhance future care planning D: Pre–post-test questionnaire (quantitative) and semi-structured interview (qualitative) study | Children and young people (0–≥16) with complex health and palliative care needs, as well as their parents and health-care providers, children n = 11 parents n = 12, bereaved parents n = 3, professionals n = 13 (qualitative outcomes), professionals (pre-study) n = 27, and professionals (post-study) n = 20 (quantitative outcomes) | Professionals evaluating My Choices on preferred: 1. Location of care 2. Diverse aspects in palliative care | 2 | 12 |
| Wiener, 2008, USA [49]  | A: To assess the acceptability of Five Wishes, helpfulness, and defining important EOL concerns D: Descriptive study data and closed- and open-response interviews | Adolescents and young adults with HIV-1 or metastatic/recurrent cancer (16–28), n = 20 | Five Wishes: 1. Age appropriateness for someone of their age 2. Helpful for someone of the participant’s age 3. Helpful or stressful to the participant | 4 | 11 |
| Wiener, 2012, USA [48]  | A: To assess and compare the usefulness, helpfulness, and stressfulness of the MTMWMV (My Thoughts, My Wishes, My Voice) with the Five Wishes D: Descriptive study data and closed- and open-response interviews | AYAs with metastatic or recurrent cancer or HIV infection (16–28), n = 52 | Evaluating both tools regarding: 1. Age appropriateness for someone of their age 2. Helpful for someone of the participant’s age 3. Helpful or stressful to the participant 4. Perceived legality of the document | 4 | 4.5 |

AYAs: adolescents and young adults; EOL: end of life; HIV: human immunodeficiency virus; NS: not specified; * Country where study was conducted.

Table 5. Evidence from qualitative studies.

| Author, Year, Country * | Aim (A), Design (D) | Population (Age in Years), n | Outcomes | Quality of Reporting Total Score |
|-------------------------|---------------------|------------------------------|----------|----------------------------------|
| Fahner, 2020, the Netherlands [11] | A: To evaluate the acceptability of content of IMPACT (Implementing Pediatric Advance Care Planning Toolkit) D: Qualitative pilot study | Children with life-limiting diseases (0–<18), children n = 27, parents n = 41, physicians n = 11, and nurses n = 7 | 1. Acceptability of materials 2. Adjustment of tool | 8.5 |
| Feraco, 2018, USA [43]   | A: To address and ameliorate existing communication gaps in cancer care and to incorporate resulting knowledge in the development of the D100 (the Day 100 talk) D: Qualitative semi-structured interview study | Children, adolescents, and young adults undergoing cancer treatment for from 1 to <7 months (≥13), as well as their parents and oncology providers, adolescents n = 5, parents n = 6, and providers n = 11 | Perceived communication gaps in cancer care | 18 |
| Author, Year, Country * | Aim (A), Design (D) | Population (Age in Years), n | Outcomes | Quality of Reporting Total Score |
|-------------------------|---------------------|-----------------------------|----------|---------------------------------|
| Finlay, 2008, UK [45]   | A: To enhance family engagement in EOL planning through incorporating the results in their $3 \times 3$ framework D: Documentary analysis study | Children with non-malignant life-limiting illnesses (2–16-months), $n = 8$ | Content of EOL plans | 4 |
| Hartley, 2016, UK [44]  | A: To evaluate the assessment of family needs and concerns by the HNA tool (Holistic Needs Assessment) D: Qualitative analysis study and qualitative pilot study | Care managers employed by Anglia’s Children’s Hospices, $n = 7$ | 1. Hopes and reservations 2. Impact on clinical practice 3. Family effect and experiences using the tool 4. Training experiences | 10.5 |

EOL: end of life; * Country where study was conducted.

Table 6. Evidence from descriptive studies.

| Author, Year, Country | Aim (A), Design (D) | Population (Age in Years), n | Outcomes | Quality Appraisal |
|-----------------------|---------------------|-----------------------------|----------|------------------|
| Baker, 2008, USA [58] | A: To assess clinical gaps in pediatric cancer care and to enhance this by integrating these aspects in the tool D: Narrative review study | Children with cancer (NS) and their parents, $n = NA$ | The development of the Individualized Care Coordination Plan | NA |
| Christenson, 2010, USA [51] | A: To present communication gaps in palliative care of adolescents and to improve this by using the CCCT (Comfort Care Communication Tool) D: Case report study | Woman with CF (18), $n = 1$ | One case study | NA |
| Curtin, 2017, USA [52] | A: To assess FACE-TC (FAmily-CEntered pediatric Advance Care Planning-Rare) efficacy on family congruence, quality of life and early ACP document completion D: Study protocol of a dyadic, longitudinal RCT | AYAs (14–20) with cancer and their family decision maker), dyads $n = 130$ | Design of dyadic, longitudinal RCT | NA |
| Dallas, 2012, USA [53] | A: To assess long-term FACE (FAmily/Adolescent-Centered Advance Care Planning) efficacy on EOL care and tries to enhance physical, psychological, spiritual well-being D: Study protocol of a dyadic, longitudinal RCT | Adolescents with HIV (14–21) and their family decision makers (>21), $n = 130$ | Design of dyadic, longitudinal RCT | NA |
| Fraser, 2010, UK [54]  | A: To present the importance of sensitive pediatric EOL planning and to describe the history and format of the Wishes document D: Narrative review study | NA (NS) | The importance of EOL planning The development of the Wishes document | NA |
| Gallagher, 2018, UK [55] | A: To highlight the importance of knowledge and skills required to engage with children with learning disabilities in their EOL planning D: Narrative review study | NA (NS) | The importance of and challenges in EOL planning ADVANCE toolkit content | NA |
Table 6. Cont.

| Author, Year, Country * | Aim (A), Design (D) | Population (Age in Years), n | Outcomes | Quality Appraisal |
|--------------------------|---------------------|-----------------------------|----------|------------------|
| Snaman, 2019, USA [59]   | A: To identify high-priority factors in cancer treatment decisions and incorporating this in a new tool D: Descriptive study of tool development | AYAs with newly diagnosed high-risk cancers (NS), their parents, and HCPs, dyads n = 5 and HCP n = 2 | Development of MyPref | NA |
| Toce, 2003, USA [60]     | A: To develop a tool that improves the pediatric quality at the EOL D: Descriptive study of tool development | Children with life-threatening conditions (6–>12 months), children n = 83 and continuity providers n = 105 | Development of Footprints | NA |
| Van Breemen, 2020, Canada [57] | A: To describe the steps in the SICG-peds (Serious illness conversations in pediatrics) using one case as an example D: Case report study | Child diagnosed with osteosarcoma (11), n = 1 | Content of the SICG-Peds | NA |
| Zadeh, 2015, USA [56]    | A: To provide guidelines in the use of Voicing My Choices for health-care providers D: Ethical guide for health-care providers for Voicing My Choices | AYAs living with cancer or pediatric HIV (NS), n = NA | Guidelines in the use of Voicing My Choices | NA |

ACP: advance care planning; AYAs: adolescents and young adults; CF: cystic fibrosis; EOL: end of life; HCP: health care provider; HIV: human immunodeficiency virus; NS: not specified; NA: not applicable; RCT: randomized controlled trial; * Country where study was conducted.

3.2. Intervention Characteristics

Table 7 presents an overview of the characteristics of the 18 pACP tools. Most interventions focused on conversations with children and their parents or surrogates as a key element of ACP [11,31,33–37,39,42–47,50,52–55,57,58,60]. Seven articles were only concerned with patients [40,48,49,51,56,59]. Two interventions targeted parents of children [38,41,47]. Some tools were used to study specific disease groups, such as oncology (n = 6) [35–39,41–43,46,52,58,59] and HIV/AIDS (n = 1) [31–34,53], whilst most tools focused on children with life-limiting conditions in general (n = 12) [11,40,44,45,47–51,54–57,60]. Twenty-five articles specified their research population’s age, ranging from zero to 28 years. Figure 2 displays the children’s ages of the target population per article. The authors of one article studied children from the age of 13 years [43]. A few studies did not specify the age of the child [44,54–56,58,59]. Nine studies researched children of all ages, including young adults [11,37,38,40,41,45,47,50,60]. Most articles were focused on adolescents and young adults [11,16,31–43,45,48–50,52,53,60], and only a few included young children [11,37,38,40,41,45–47,50,57,60]. Three studies described a specific age in their research population but did not explain their choice of this age [46,51,57]. Among those intervening in the care were a broad diversity of clinicians including pediatricians, nurses, clinicians, and unspecified certified facilitators. Conversation topics included: disclosing hopes, wishes, goals (of care), preferences for care and treatment, family and patient needs, and the planning of future or end-of-life care. The ACP was approached as a longitudinal face-to-face process with multiple conversations. Most articles did not specify the race or ethnicity of their target population [11,40,43–45,50–52,54–60]. The most common population backgrounds were Caucasian [35,36,38,41,42,46,47,49] and African American [31–34,39,48,53]. The importance of a culturally appropriate pACP intervention was mentioned in most articles (n = 20) [11,31–36,42,44,45,47,48,50,52–56,58,60].
| Intervention (Country) | Intervention Characteristics | Aim | Interventionist | Target Population | Publications Included |
|------------------------|-------------------------------|-----|-----------------|-------------------|-----------------------|
| 1. Comfort Care Communication Tool (USA) | Ma: Four-quadrant design document Mo: Face-to-face longitudinal conversations Se: NS | To enhance adolescents’ disclosure and person-centered care based on families’ goals | Pediatric Advanced Comfort Care Team Nurse | Adolescents with life-threatening or life-limiting health care conditions | Christenson, 2010 [51] |
| 2. Family-Centered pediatric Advance Care Planning (USA) | Ma: Family-centered ACP survey (session 1), Respecting Choices interview (session 2), and Five Wishes document (session 3) Mo: Three-session face-to-face conversation Se: Outpatient clinic | To facilitate EOL discussions for adolescents and their families | Certified facilitator | Adolescents with cancer, HIV or AIDS and their surrogates | Curtin, 2017 [52] Dallas, 2012 [53] Dallas, 2016 [31] Friebert, 2020 [42] Jacobs, 2015 [39] Lyon, 2009 [32] Lyon, 2010 [34] Lyon, 2013 [35] Lyon, 2014 [36] |
| 3. Family-Centered pediatric Advance Care Planning Rare (USA) | Ma: Conversation card, documentation tool Mo: Four-session interviews, face-to-face or via telemedicine conversation Se: NS | To identify and meet caregiver-centered palliative care needs | Certified clinician | Family caregivers of children and adolescents with rare diseases | Lyon, 2019 [47] |
| 4. Implementing Advance Care Planning Toolkit (NL) | Ma: Information leaflets, preparation cards (child and parent), and conversation guides Mo: Face-to-face conversations, on-off conversation, or multiple conversations Se: Home, inpatient, or outpatient clinic | To prepare children, clinicians and parents for future care, to guide documentation, and to elicit the voice of the child and stimulate a patient-centered approach | Clinician involved in the patient’s care | Children with life-limiting conditions and their families | Fahner, 2020 [11] |
| 5. DAY 100 Talk (UK) | Ma: Family preparatory and summary worksheet and a conversation guide Mo: Fill in up-front and face-to-face longitudinal conversations Se: Outpatient clinic | To enhance families’ disclosure and interdisciplinary guidance | Trained pediatric oncologist and psychosocial clinician | Children, adolescents, and young adults with cancer and their families | Feraco, 2018 [43] |
| 6. 3 × 3 Lifetime Framework (UK) | Ma: 3 × 3 Framework Document Mo: Face-to-face longitudinal conversations Se: NS | To enhance family engagement in EOL planning | Clinicians | Children with non-malignant, life-limiting illnesses and their families | Finlay, 2008 [45] |
| 7. The Wishes Document (UK) | Ma: Hand-held document Mo: Face-to-face longitudinal conversations Se: NS | To enhance family engagement in EOL planning | Clinician involved in the patient’s care | Children, young people with life-limiting conditions and their families | Fraser, 2010 [54] |
| 8. The ADVANCE toolkit (UK) | Ma: Ethical guide Mo: Face-to-face longitudinal conversations Se: Private place | To enhance provider guidance, families’ disclosure, and families’ engagement in EOL planning | Clinician involved in the patient’s care | Young persons with learning disabilities (who are approaching the end of life) and their families | Gallagher, 2018 [55] |
| 9. Holistic Needs Assessment (UK) | Ma: Comprehensive assessment of needs Mo: Face-to-face conversation Se: NS | To enhance person-centered care based on family needs | Senior member of staff | Children in palliative care settings and their family | Hartley, 2016 [44] |
| Intervention (Country) | Intervention Characteristics | Aim | Interventionist | Target Population | Publications Included |
|-----------------------|-----------------------------|-----|------------------|-------------------|-----------------------|
| 10. Decision-making Communication Tool (USA) | Ma: Four domains of decision making  Mo: Face-to-face longitudinal conversations  Se: Outpatient clinic | To enhance patient-provider communication, decision making, and quality of life, as well as to identify goals of care | Supportive care team clinicians | Pediatric palliative care: infants, children, and adolescents with potentially life-limiting illnesses (oncology) and their families | Kline, 2012 [46]  Hays, 2006 [37] |
| 11. Communication Plan: Early through End of Life (USA) | Ma: Conversation guide and visual aids  Mo: Three face-to-face conversation sessions, longitudinal revision  Se: During clinic appointments | To reduce parental distress | Trained oncology providers | Parents of children with cancer | Hendricks, 2017 [38]  Moody, 2020 [41] |
| 12. Voicing my choices (USA) | Ma: Guide adapted from the Five Wishes, completion of the document guide  Mo: Longitudinal revision  Se: NS | To enhance communication between the patient and caregiver in EOL preferences and care | Clinicians | Adolescents and young people living with a serious illness | Wiener, 2012 [48]  Kazmerski, 2016 [40]  Zadeh, 2015 [56] |
| 13. My Choices/Choices for My Child Booklets (UK) | Ma: Booklets for children and parents, possibility Mo: To fill in/initiate thinking or face-to-face conversations  Se: Home or outpatient clinic | To enhance family engagement in future planning and the disclosure of family preferences | NA | Children with life-limiting conditions from diagnosis onwards and their parents | Noyes, 2013 [50] |
| 14. The Serious Illness Conversation Guide-Peds (SICG-Peds) (Canada) | Ma: Conversation guide  Mo: Longitudinal face-to-face or by phone conversations  Se: Home or clinic | To enhance understanding of illness and care preferences | Trained pediatrician | Children with serious illness and their parents | Van Breemen, 2020 [57] |
| 15. Five Wishes® (USA) | Ma: Legal document consisting of five wishes  Mo: Fill in document  Se: NS | To enhance communication in EOL care | Clinicians | Adolescents and young adults living with serious illnesses | Wiener, 2008 [49] |
| 16. Individualized care planning and coordination (USA) | Ma: Advance care planning documentation tool  Mo: Longitudinal revision on timely basis  Se: NS | To facilitate integration of palliative care into ongoing care | Clinicians | Children with cancer and their parents | Baker, 2008 [58] |
| 17. MyPref (USA) | Ma: Preference report up-front cancer therapy  Mo: Fill in document, longitudinal revision  Se: NS | To clarify AYAs’ preferences and to enhance engagement in medical decision making | Oncology providers or other clinicians | AYA patients with relapsed/progressive cancer | Snaman, 2019 [59] |
| 18. FOOTPRINTS (USA) | Ma: Conversation guide, using a discharge order sheet  Mo: Longitudinal face-to-face conversations  Se: During the interdisciplinary “care conference” | To provide quality of care for the patient, their families, and providers through anticipating their needs on a continual basis | Hospital-based “continuity” pediatrician | Children with life-limiting illnesses and their families | Toce, 2003 [60] |

AYA: adolescents and young adults; ACP: advance care planning; AIDS: acquired immunodeficiency syndrome; EOL: end of life; HIV: human immunodeficiency virus; NA: not applicable; NS: not specified.
3.3. Attention to Age Appropriateness

Age-appropriate characteristics are summarized in Table 8. The concept of an age-appropriate approach was mentioned in two thirds of the articles [11,32,33,35–37,42,44,48–60] in an implicit or explicit way. However, no clear definition of an age-appropriate approach in pACP was described. Seventeen articles mentioned the age-appropriate concept in an implicit or explicit way without linking the importance of adapting the tools to the development of the child [35–37,40,42,44,48–55,57,58,60]. An example of an implicit description of the age-appropriate concept is cited in Box 1.

**Box 1. Example of implicit description of the concept of age appropriateness.**

"Most adolescents aged 14 years and older do not differ from adults in their capacity to make informed treatment decisions, and their understanding of death is no less mature than that of adults" [42] (p. 2).

Few articles referred to the concept in an explicit way by describing any implications of using the concept [11,32,33,56,59]. An explicit description of the age-appropriate concept is presented in Box 2.

**Box 2. Example of explicit description of the concept of age appropriateness.**

"Developmentally, the AYA period is characterized by emerging abstract thinking and an evolving sense of vulnerability. Given this complex developmental stage, AYA patients may benefit from the use of specialized tools to facilitate abstract consideration of factors involved in decision making" [59] (p. 2).

Although most articles referred to age appropriateness as a concept in some way, this was generally not translated into specific elements of the described tools nor specified for different levels of development. Twelve articles provided general recommendations to implement age appropriateness in pACP tools [11,32,37,48–51,54–56,58,59]. Fourteen

![Figure 2. Age range in study population per article [11,31–60].](image-url)
studies claimed their tools to be age-appropriate [11,32,33,36,48–53,56,59,60], yet only seven articles implemented elements adjusted to the age of their population. Most of these articles adapted the language to the child’s age [11,48,50,51,56,57], used age-appropriate images [49,50], or added a glossary [48,56]. One article referred to their pACP guide as containing family-centered language [57]. These elements mainly focused on adolescents and young adults [48,49,51] or did not specify a particular age of their target population [56,57]. None of the articles explained why these adaptations meet the development needs or capacities of studied children nor explored the development needs of children in general.

Another way to contribute to the age-appropriate concept was by evaluating a tool for its age appropriateness. Most articles did not report any empirical study data regarding the age appropriateness of the tool used by participants. Twenty-eight studies described or evaluated the effectiveness and the child and family preferences of their tools, but none of them specifically evaluated their age appropriateness [11,31–39,41–47,50–60]. Only three studies examined the age appropriateness of their tool by asking adolescents and young adults if the tool was considered appropriate for themselves and other participants of their age [40,48,49]. The development stage or capacities to participate in the pACP of the children were not described or researched. None of the articles examined age appropriateness in young children. Age-appropriate outcomes were reported by providers in one article [40] and by AYAs in three articles [40,48,49]. These studies showed that AYAs considered pACP tools to be age-appropriate [40,49] and could be introduced before the age of 18 [40]. AYAs experienced the tools as helpful [49]. Only one article examined the perspective of the providers, revealing that pACP tools were considered less appropriate for AYAs and therefore contradicting AYAs’ opinion on age appropriateness. About half of the providers reported thinking that pACP conversations should occur after the age of 18 [40].

Table 8. Age-appropriate characteristics.

| Article          | Description Concept | Implementation in the Tool Described | Evaluation on Age Appropriateness Stated by Patient/Provider/Family | Recommendations |
|------------------|---------------------|-------------------------------------|-------------------------------------------------------------------|-----------------|
| Baker, 2008 [58] | Implicit            | No                                  | NS                                                                | NS              |
| Christenson, 2010 [51] | Implicit          | Yes                                 | Questions adjusted for age and maturity                           | Yes             |
| Curtin, 2017 [52] | Implicit            | Yes                                 | NS                                                                | NS              |
| Dallas, 2012 [53] | Implicit            | Yes                                 | NS                                                                | NS              |
| Dallas, 2016 [31] | No Description      | No                                  | NS                                                                | No              |
| Fahner, 2020 [11] | Explicit            | Yes                                 | Booklets and conversation guides, with language adapted to the children | Yes             |
| Feraco, 2018 [43] | No Description      | No                                  | NS                                                                | No              |
| Finlay, 2008 [45] | No Description      | No                                  | NS                                                                | No              |
| Fraser, 2010 [54] | Implicit            | No                                  | NS                                                                | Yes             |
| Friebert, 2020 [42] | Implicit           | No                                  | NS                                                                | No              |
| Gallagher, 2018 [55] | Implicit        | No                                  | NS                                                                | No              |
| Hartley, 2016 [44] | Implicit            | No                                  | NS                                                                | No              |
| Hays, 2006 [37]   | Implicit            | No                                  | NS                                                                | Yes             |
| Hendricks, 2017 [38] | No Description    | No                                  | NS                                                                | No              |
| Jacobs, 2015 [39] | No description      | No                                  | NS                                                                | No              |
Table 8. Cont.

| Article                | Description Concept | Implementation in the Tool Described | Statement of Concept Applied | Elements of Tool | Evaluation on Age Appropriateness Stated by Patient/Provider/Family | Recommendations |
|------------------------|---------------------|--------------------------------------|------------------------------|-----------------|---------------------------------------------------------------------|-----------------|
| Kazmerski, 2016 [40]   | Implicit            | No                                   | NS                           | 90% considered VMC (Voicing My Choices) to be age-appropriate; 66% considered ACP to be appropriate to introduce before the age of 18 or at any age | 58% considered VMC to be appropriate for patient population/age group; 50% found the ideal patient age for ACP discussion was >18 years | NS             |
| Kline, 2012 [46]       | No Description      | No                                   | NS                           | NS              | NS                                                                  | No              |
| Lyon, 2009 [32]        | Explicit            | Yes                                  | NS                           | NS              | NS                                                                  | No              |
| Lyon, 2009 [33]        | Explicit            | Yes                                  | NS                           | NS              | NS                                                                  | No              |
| Lyon, 2010 [34]        | No Description      | No                                   | NS                           | NS              | NS                                                                  | No              |
| Lyon, 2013 [35]        | Implicit            | No                                   | NS                           | NS              | NS                                                                  | No              |
| Lyon, 2014 [36]        | Implicit            | Yes                                  | NS                           | NS              | NS                                                                  | No              |
| Lyon, 2019 [47]        | No Description      | No                                   | NS                           | NS              | NS                                                                  | No              |
| Moody, 2020 [41]       | No Description      | No                                   | NS                           | NS              | NS                                                                  | No              |
| Noyes, 2013 [50]       | Implicit            | Yes                                  | Booklets content and images adapted for age | NS              | NS                                                                  | Yes             |
| Snaman, 2019 [59]      | Explicit            | Yes                                  | NS                           | NS              | NS                                                                  | Yes             |
| Van Breemen, 2020 [57] | Implicit            | Yes                                  | Family-centered language     | NS              | NS                                                                  | No              |
| Wiener, 2008 [49]      | Implicit            | Yes                                  | Age-appropriate images       | 90% declared that all statements on EOL care were appropriate and helpful for someone their age | NS              | NS                                                                  | Yes             |
| Wiener, 2012 [48]      | Implicit            | Yes                                  | Wording and questions adjusted for development and a glossary added | No significant tool differences in the degree of help or stress in age groups or differences in document content; AYAs disagreed on whether medical care wishes in the Five Wishes versus MTMWMV (My Thoughts, My Wishes, My Voice) was more appropriate for someone of their age | NS              | NS                                                                  | Yes             |
| Zadeh, 2015 [56]       | Explicit            | Yes                                  | Wording and questions adjusted for development and a glossary added | NS              | NS                                                                  | No              |
| Toce, 2003 [60]        | Implicit            | Yes                                  | NS                           | NS              | NS                                                                  | No              |

ACP: advance care planning; AYA: adolescents and young adults; EOL: end of life; NS: not specified.
3.4. Factors Influencing Age Appropriateness

We identified four factors related to age appropriateness that might influence the pACP approach: willingness to participate, ability to participate, social identity, and legal responsibilities. How these factors function at certain development stages was not clearly described. Table 9 shows an overview of these factors per article. Articles were marked with an ‘x’ when contributing to this factor.

Table 9. Factors related to age appropriateness.

| Study                  | Willingness to Participate | Ability to Participate | A Child’s Understanding of Their Own Medical Process | Cognitive Impairment | Developing Social Identity | Legal Responsibilities |
|------------------------|---------------------------|------------------------|---------------------------------------------------|-----------------------|---------------------------|------------------------|
| Baker, 2008 [58]       | x                         | x                      |                                                   |                       |                           |                        |
| Christenson, 2010 [51] | x                         | x                      |                                                   |                       |                           |                        |
| Curtin, 2017 [52]      |                           |                         | x                                                 |                       |                           |                        |
| Dallas, 2012 [53]      | x                         | x                      | x                                                 | x                     |                           |                        |
| Dallas, 2016 [31]      | x                         |                         |                                                   |                       |                           |                        |
| Fahner, 2020 [11]      | x                         | x                      |                                                   |                       |                           |                        |
| Feraco, 2018 [43]      |                           |                         |                                                   |                       |                           |                        |
| Finlay, 2008 [45]      |                           |                         |                                                   |                       |                           |                        |
| Fraser, 2010 [54]      |                           | x                      |                                                   |                       |                           |                        |
| Friebert, 2020 [42]    | x                         | x                      | x                                                 | x                     |                           |                        |
| Gallagher, 2018 [55]   | x                         | x                      |                                                   |                       |                           |                        |
| Hartley, 2016 [44]     |                           |                         |                                                   |                       |                           |                        |
| Hay, 2006 [37]         |                           |                         |                                                   |                       |                           |                        |
| Hendricks, 2017 [38]   |                           |                         |                                                   |                       |                           | x                      |
| Jacobs, 2015 [39]      | x                         |                         |                                                   |                       |                           |                        |
| Kazmerski, 2016 [40]   |                           |                         |                                                   |                       |                           |                        |
| Kline, 2012 [46]       |                           |                         |                                                   |                       |                           |                        |
| Lyon, 2009 [32]        | x                         | x                      |                                                   | x                     |                           | x                      |
| Lyon, 2009 [33]        | x                         | x                      | x                                                 | x                     |                           | x                      |
| Lyon, 2010 [34]        | x                         |                         |                                                   |                       |                           | x                      |
| Lyon, 2013 [35]        | x                         | x                      | x                                                 | x                     |                           | x                      |
| Lyon, 2014 [36]        | x                         | x                      | x                                                 | x                     |                           | x                      |
| Lyon, 2019 [47]        |                           |                         |                                                   |                       |                           |                        |
| Moody, 2020 [41]       |                           |                         |                                                   |                       |                           |                        |
| Noyes, 2013 [50]       |                           |                         |                                                   |                       |                           |                        |
| Snaman, 2019 [59]      | x                         |                         |                                                   |                       |                           | x                      |
| Toce, 2003 [60]        |                           |                         |                                                   |                       |                           |                        |
| van Bremen, 2020 [57]  |                           |                         |                                                   |                       |                           | x                      |
| Wiener, 2008 [49]      | x                         | x                      |                                                   |                       |                           |                        |
| Wiener, 2012 [48]      | x                         | x                      | x                                                 | x                     |                           | x                      |
| Zadeh, 2015 [56]       | x                         | x                      | x                                                 | x                     |                           | x                      |
Sixteen articles stated that children, especially AYAs, show a willingness to participate in pACP conversations [11,31–36,39,40,42,43,48,51,53,56,59]. Articles explored the child’s willingness to participate by asking this to the children themselves and their parents. Willingness reflects the motivation of the child to be involved in a pACP conversation and clarifies to what extent this may be so. Many articles cited previous research on this subject, which showed that adolescents and young adults have a desire to participate in pACP. Few declared the same desire among young children and teenagers [11,34,43,56].

Another factor we identified was the ability to participate in pACP. This was referred to by three different sub-themes. Firstly, multiple articles reported that children and adolescents are cognitively able and sufficiently mature to make decisions, medical or otherwise, and that they therefore should be involved in pACP [11,32,35,36,42,44,48,49,51,53–56,58,60]. Most articles did not specify which cognitive capacities are needed but described cognitive capacities in general. The second sub-theme was the understanding of how a child’s own disease process contributes to their participation in pACP. This may indicate whether or not they are able to understand the content of a pACP conversation [33,35,36,42,48,49,51,53,55–59]. The subjects we identified were an understanding of the consequences of decision making [33,35,36,58], medical concepts (health, illness, death) [36,42,48,51,55,57,59], and an understanding of treatment decisions in general [36,55,56,58]. The final sub-theme was cognitive impairment. Many articles excluded patients with cognitive impairment because they experienced this as limiting or complicating age-appropriate pACP [31–36,39,42,43,52,53]. However, separate from decision-making capacity and understanding, cognitive impairment was identified as a factor on its own that influences the ability of a child to participate in conversations.

Five articles described a developing social identity in adolescence as a factor related to age appropriateness [32,48,51,55,56]. During adolescence, children develop an awareness of themselves and others, which influences children’s preferences and goals in pACP.

Some articles described the law requesting an advance directive, or living will, starting from a certain age [31,33,34,38,39,48,49,53,56]. These legal documents or conversations were sometimes described as part of the pACP conversations. Laws determine what is considered a legal age in participating in own health-care decisions. In some articles, younger age groups (18 years old or younger) were excluded from such topics or conversations [31,33,34,38,39,48,53,56].

4. Discussion

To our knowledge, this is the first systematic review examining age-appropriate characteristics and outcomes in pACP interventions for children with life-limiting conditions. Thirty-one articles reporting on 18 unique pACP tools were identified. Although pACP is aimed to emphasize the preferences and goals of children and their parents, the voices of children are explored by the interventions to a very limited extent. Two thirds of the studied articles referred to the age-appropriate concept; however, none of the studies comprehensively examined the development stage of their target population. Few interventions contained elements adjusted to the development of the child, or evaluated the intervention on age appropriateness [40,48,49]. The factors contributing to age appropriateness identified from the studies we investigated were: willingness to participate, ability to participate, developing a social identity, and legal responsibilities.

4.1. Defining Age Appropriateness in pACP

In this review, we have defined age appropriateness as the level of cognitive development of a child corresponding to a certain age. Cognitive development can differ between individuals of the same age and can fluctuate in children with life-limiting conditions [61–63]. Age-appropriate pACP tools would therefore benefit from adjustments to the development stage of a child with a life-limiting illness.

In this review, we identified different factors (willingness to participate, ability to participate, legal responsibilities and social identity) that might characterize or influence
the development stage. Piaget described different stages in cognitive development in children [17]. The literature is not, however, clear about whether these stages could be used for children with life-limiting illnesses. However, it does provide general information on the development capacities and the comprehension of topics related to ACP. As ACP is intended to be used to discuss future care preferences, children might benefit from an understanding of the medical concepts involved and also from a greater role in medical decision making. A review of medical decision making in children and adolescents showed that four cognitive capacities are needed: communicating a choice, understanding, reasoning, and appreciation [64]. In this way, the development stage of the child, with corresponding cognitive capacities, determines their ability in medical decision making. Expressing a choice, the first criterion, can either be accomplished via language or non-verbal communication [65,66]. Starting from the age of five years, children have a proper understanding of language, and this is a first step towards medical decision making. Non-verbal communication helps in assessing a child’s preferences but is excluded as legal consent [67]. The second criterion, understanding information on one’s own medical treatment, requires different neurological capacities in decision making [65,66]. Previous studies have shown that children from the ages of seven to ten years can orient and maintain attention [68–70], those from six to 12 years old can memorize [71,72], and those from the age of ten years old can recall received information [73–75]. Aside from understanding information on treatment, the comprehension of sub-concepts such as illness, life, and death depends on the cognitive understanding of death as a biological act [76–80]. This can be fully understood starting from the ages of five to seven years old [78–81]. The understanding of sub-concepts such as irreversibility, universality, personal mortality, inevitability, causality, and unpredictability might even begin at the age of three [77–81]. The articles we researched provided some basis to this theory, implying that children, starting from a young age, should not be excluded from these topics in pACP. Children from the ages of six to eight years can logically reason [82,83] about decision-making consequences, including risks and benefits, which is the third criterion [65,66,84]. This capacity further develops in adolescence, therefore meaning that they can understand more complex issues [82]. Few of the articles we researched mentioned that children can understand the consequences of decisions, indicating that children are able to reason regarding logically their own pACP decisions and should therefore be included in weighing different treatment options. The last criterion, appreciation, indicates that children from the ages of three to four years start recognizing their own norms and values, as well as the effect of these on their own life [67,85,86]. This implies that preferences and hopes in pACP could be explored in a more simple manner and early in childhood. Most studied articles focused on pACP interventions for older children and may have underestimated the value for younger children. Adolescence is considered an interesting development phase in decision making in which children develop a social identity and awareness of themselves and their peers [87]. They highly value the acceptance of peers, which influences decision making [88]. Adolescents make more decisions offering swift rewards in the presence of the other peers [89]. Altogether, Grootens-Wiegers et al. stated that children from the age of 12 are expected to be competent in decision making [64]. Legally, children from the age of 12 years are allowed to make joint decisions on medical issues with their parents. From the age of 16, they can make decisions on their own [90]. In the USA starting from the age of 18 they are allowed to give informed consent for participating in clinical trials [91]. pACP can play a valuable role in preparing children for decision making. However, ACP was not developed for contemporaneous medical decision making; rather, it was developed for preparing certain decisions in the future. In this way, children can participate and have a feeling of control in their own disease process. This can only be achieved when the child’s level of development is assessed as part of pACP or prior to the initiation of pACP.

We identified cognitive impairment as a factor influencing the concept of development. Approximately half of the children with life-limiting illnesses also suffer a degree of cognitive impairment [92]. Multiple articles excluded children with cognitive impairment,
indicating that it could complicate participation in pACP. Cognitive impairment is defined as a deficiency in cognitive function consisting of multiple capacities: memory, general intelligence, learning new things, language, orientation, perception, attention, and concentration and/or judgment [93]. Cognitive impairment is a broadly used term in which one or more cognitive functions are affected in general. Engaging these children in pACP would therefore benefit from adaptations to the development of their cognitive functions.

Most pACP articles on children with life-limiting conditions reported that pACP interventions need to be culturally appropriate. Preferences in discussing pACP topics differ between cultures [94]. However, the literature is not clear what is considered age-appropriate pACP participation in different cultures. Cognitive development, and therefore level of the child’s participation in conversations and decision making, is influenced by cultural differences that affect parenting roles, government guidelines and education [95]. To involve children in pACP in an adequate and age-appropriate manner, their ethnical background should be considered.

Even though defining different stages in the development of children with life-limiting illnesses would be helpful, evidence indicates that the development, cognitive or otherwise, of a child is an individual, fluctuating, culturally-dependent and differentiating process with regard to different topics [61–63]. The development of a child can progress or regress individually during the life or disease process. When a child deteriorates, cognitive development can regress and changes in level of development and rate of assent could appear [90]. On the other hand, clinical experience has shown that children, especially adolescents, with life-limiting illnesses often seem to have a better understanding of death and dying compared to healthy children of their age [61]. This can be due to their greater experience with death than other children of their age [62]. However, the literature is inconsistent. Experiencing death through media [62] and what parents teach their children about biology and natural processes [63] stimulates children with regard to the concept of death and dying [62,63]. Diverse ACP topics might have different levels of development in one individual. A comprehension of life and death is only one aspect of the topics discussed in pACP. Other topics, such as preferences and hopes in general, could be easier for children to talk about and could be comprehended on another level of development. The comprehension of diverse topics in pACP differs in the development in children and should therefore determine their level of participation in that topic. The comprehension of one’s own body, for example, develops between the ages of four to six years [96], while the understanding of death develops later, between the ages of five and seven years [62,78–81].

4.2. Recommendations for Future Research

Development is an individual, fluctuating, culturally dependent, and differentiating process between topics and cognitive functions. The stage of development, rather than age, therefore gives direction in how to appropriately engage children with regard to their development. Research is needed to identify the specific characteristics of each development stage for children with life-limiting conditions. Elements that depend upon developments can then be determined and incorporated to create age-appropriate pACP interventions. Most pACP tools lack a comprehensive inclusion or description of age-appropriate pACP elements. Current literature on pACP does not provide sufficient insight in characteristics of age-appropriate elements. This complicates the appraisal of the usefulness of current tools. Two interventions were evaluated on age appropriateness by their target population of AYAs and their providers [40,48,49]. They were considered acceptable and useful for this age group. Age-appropriate elements, such as language and images, were incorporated, but an explanation of why these elements met the child’s developmental needs and capacities was lacking. Examining the intervention by the target population provides a first indication of the level of age appropriateness of a tool. However, more insight is needed regarding which development characteristics apply to certain age groups that are relevant in pACP. In this way, a framework of age-appropriate pACP elements can be designed and incorporated into existing and newly developed
interventions. pACP tools can be ranked for their level of age appropriateness, which might be an indicator of high-quality family-centered tools. We were not able to apply any qualification to the level of age appropriateness of the pACP tools studied in this review without such a framework.

Creating and examining different stages in development for children with life-limiting illnesses would benefit from other fields of expertise. Experts in developmental psychology, even children themselves and their families, could determine what information or elements are considered age-appropriate [40,48,49]. The development stage should be frequently assessed because it fluctuates, which may require a separate tool. Creating an intervention that determines the level of development of a child regarding pACP topics could provide an indication of how clinicians can involve children in pACP conversations, e.g., which topics providers have to raise or questions to ask. The same fluctuating cognitive phenomena have been observed in dementia patients [97,98] in which cognitive capacities for ACP participation were assessed [97,99]. The literature shows that even patients with severe dementia can still share their preferences or wishes on a certain level [99]. Therefore, we should always explore children’s cognitive development and involve children in their own disease processes on a level that corresponds with their cognitive capacities.

Future research should investigate what is considered age-appropriate participation in different cultures, which has not yet been described in the literature. In creating an age-appropriate intervention, cultural norms and values should be incorporated to involve children in a way that is appropriate for their developmental stage.

4.3. Strengths and Limitations

This systematic review contributes to the body of knowledge of the young and evolving field of pACP. The research team assessed the content and characteristics of different pACP tools regarding age appropriateness. A team offering broad expertise evaluated the different aspects of age appropriateness. This review comprises the first steps towards the incorporation of age appropriateness in pACP. The results show that age appropriateness is considered important; however, the comprehensive elaboration of this concept is still in its infancy. These findings limit the opportunities for clinical implications for current practice while emphasizing the need for ongoing research to be able to develop a comprehensive age-appropriate approach in pACP. In addition, the variety of different study designs complicates any comparison of the role of the separate intervention elements. pACP may be an upcoming field of expertise, but it is still relatively new in advance care planning and there might be more influencing factors than we have discovered. Other fields of expertise might contribute to these factors. Most reviewed articles were published and conducted in the USA. This might limit the applicability of the findings to other countries. The USA articles were mainly dominated by one research group, which might have biased the results.

5. Conclusions

In this review, we have summarized the age appropriateness of existing pACP tools in children with life-limiting conditions. The relevance of an age-appropriate approach was mentioned in most articles, though mainly in an implicit way. None of the articles comprehensively examined the development stage of their target population. Four factors influencing age appropriateness were identified: willingness to participate, ability to participate, developing social identity, and legal responsibilities. Three articles evaluated their tools regarding age appropriateness. The tools integrated age-appropriate elements to a very limited extent, mainly focusing on adolescents and young adults. The involvement of children of all ages in pACP needs a more comprehensive approach.
Author Contributions: Conceptualization and methodology, J.F., M.L., E.M. and M.K.; data collection: M.L., K.P., K.K.; formal analysis, J.B., J.F. and M.L.; writing—original draft preparation, J.B. and J.F.; writing—review and editing, J.B., J.F., M.L., E.v.d.B., K.K., K.P., M.K. and E.M.; visualization, J.B.; supervision, E.M.; project administration, E.M.; funding acquisition, E.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Porticus grant number 100035_I5258294.

Institutional Review Board Statement: Not applicable, this study did not involve humans or animals.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We thank our information specialist, who helped us in developing the search string and conducting the search. We would like to thank Tony Sheldon and David Brunetta for reading and correcting the grammar and syntax of our review.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Appendix A

Tables A1–A3 show a score overview per article, conducting the risk of bias and quality of reporting assessment.

Table A1. Risk of bias assessment trials according to Cochrane risk of bias tool.

| Study             | Random sequence generation | Allocation concealment | Blinding of participants | Blinding of outcome assessment | Incomplete outcome data | Total score (6) |
|-------------------|-----------------------------|------------------------|--------------------------|-------------------------------|------------------------|-----------------|
| Dallas, 2016 [31] | +                           | +                      | -                        | +                             | +                     | 5               |
| Lyon, 2009 [32]   | +                           | +                      | -                        | ?                             | +                     | 3               |
| Lyon, 2009 [33]   | +                           | +                      | -                        | ?                             | -                     | 3               |
| Lyon, 2010 [34]   | +                           | +                      | -                        | -                             | -                     | 3               |
| Lyon, 2013 [35]   | +                           | +                      | -                        | -                             | -                     | 3               |
| Lyon, 2014 [36]   | +                           | +                      | -                        | -                             | -                     | 3               |

+ = criterion with low risk of bias, a score of one point was assigned; - = criterion with high risk of bias, a score of zero points was assigned; ? = criterion with unclear risk of bias, no score was assigned.

Table A2. Risk of bias assessment observational studies according to an adapted risk of bias assessment tool.

| Study             | Random sequence generation | Allocation concealment | Blinding of participants | Blinding of outcome assessment | Incomplete outcome data | Total score (6) |
|-------------------|-----------------------------|------------------------|--------------------------|-------------------------------|------------------------|-----------------|
| Hayes, 2006 [37]  | +                           | +                      | -                        | +                             | +                     | 5               |
| Hendricks, 2017 [38] | +                           | +                      | -                        | +                             | +                     | 5               |
| Jacobs, 2015 [39] | +                           | +                      | -                        | +                             | +                     | 5               |
| Kazmerski, 2016 [40] | +                           | +                      | -                        | +                             | +                     | 5               |
| Kline, 2012 (MM) [46] | +                           | +                      | -                        | -                             | -                     | 3               |
| Lyon, 2019 (MM) [47] | +                           | +                      | -                        | -                             | -                     | 3               |
| Moody, 2020 [41]  | +                           | +                      | -                        | -                             | -                     | 3               |
| Wiener, 2008 (MM) [48] | +                           | +                      | -                        | -                             | -                     | 3               |
| Wiener, 2012 (MM) [48] | +                           | +                      | -                        | -                             | -                     | 3               |
| Frieden, 2020 [42] | +                           | +                      | -                        | -                             | -                     | 3               |
| Noyes, 2013 (MM) [50] | +                           | +                      | -                        | -                             | -                     | 3               |

1. Selection process of study population

+ = criterion with low risk of bias, a score of one point was assigned; - = criterion with high risk of bias, a score of zero points was assigned; ? = criterion with unclear risk of bias, no score was assigned.
### Table A2. Cont.

|                                            | Hays, 2006 [37] | Hendricks, 2017 [38] | Jacobs, 2015 [39] | Kazmierski, 2016 [40] | Kline, 2012 (MM) [46] | Lyon, 2019 (MM) [47] | Moody, 2020 [41] | Wiener, 2008 (MM) [48] | Wiener, 2012 (MM) [49] | [50] |
|--------------------------------------------|-----------------|----------------------|------------------|----------------------|---------------------|---------------------|-----------------|----------------------|---------------------|------|
| 2. Comparability of compared groups        | NA              | NA                   | NA               | NA                   | NA                  | NA                  | NA              | NA                   | NA                   | NA   |
| 3. Standardized protocol for the use of the ACP tool | -               | +                    | +                | -                    | +                   | +                   | +               | +                    | +                    | +    |
| 4. Standardized protocol for measuring the outcome | +               | +                    | +                | -                    | +                   | +                   | +               | +                    | +                    | +    |
| 5. Missing data with regard to inclusion of follow-up or incomplete data | +               | +                    | +                | -                    | -                   | -                   | -               | -                    | +                    | -    |
| 6. Adjustment for confounders              | -               | -                    | NA               | NA                   | +                   | -                   | -               | NA                   | +                    | NA   |
| 7. Selective outcome reporting             | +               | +                    | +                | -                    | +                   | +                   | +               | +                    | +                    | -    |
| Total score (out of 7)                     | 4               | 5                    | 5                | 2                    | 4                   | 4                   | 4               | 4                    | 6                    | 2    |

+ = criterion with low risk of bias, a score of one point was assigned; - = criterion with high risk of bias, a score of zero points was assigned; ? = criterion with unclear risk of bias, no score was assigned; MM = mixed methods; NA: Not Applicable.

### Table A3. Quality of reporting in qualitative studies according to the Comprehensive consolidated criteria for Reporting Qualitative research.

|                                            | Fahner, 2020 [11] | Feraco, 2018 [43] | Finlay, 2008 [45] | Hartley, 2016 [44] | Noyes, 2013 (MM) [50] | Kline, 2012 (MM) [46] | Lyon, 2019 (MM) [47] | Wiener, 2012 (MM) [48] | Wiener, 2008 (MM) [49] |
|--------------------------------------------|-------------------|-------------------|-------------------|---------------------|----------------------|---------------------|---------------------|----------------------|----------------------|
| 1. Interviewer/facilitatorc                | +/-               | +                 | -                 | +/-                | +/-                 | -                   | -                   | +                    | -                    |
| 2. Credentials                             | -                 | +                 | -                 | -                   | -                   | -                   | -                   | +                    | -                    |
| 3. Occupation                              | -                 | -                 | -                 | -                   | -                   | -                   | -                   | -                    | -                    |
| 4. Gender                                  | -                 | +                 | -                 | -                   | -                   | -                   | -                   | -                    | -                    |
| 5. Experiences or training                 | -                 | -                 | -                 | -                   | -                   | -                   | +/-                | -                    | +                    |
| 6. Relationships established               | -                 | -                 | -                 | -                   | -                   | -                   | -                   | -                    | -                    |
| 7. Participant knowledge of the interviewer| -                 | -                 | -                 | -                   | -                   | -                   | -                   | -                    | -                    |
| 8. Interviewer characteristics             | -                 | -                 | -                 | -                   | -                   | -                   | -                   | -                    | -                    |
| 9. Methodological orientation              | +                 | +                 | +                 | +                   | +                   | +                   | +                   | -                    | +                    |
Table A3. Cont.

| 10. Sampling | - | + | - | - | + | - | - | - | - |
| 11. Method of approach | - | + | - | - | - | + | - | - | - | - |
| 12. Sample size | + | + | + | + | + | + | + | + | + | + |
| 13. Non-participation | - | +/- | - | - | + | +/- | +/- | - | + | + |
| 14. Setting of data collection | - | +/- | - | - | +/- | - | - | - | - | - |
| 15. Presence of non-participants | - | - | - | - | - | - | + | - | - | - |
| 16. Description of sample | + | + | +/- | - | +/- | - | + | + | + | + |
| 17. Interview guide | - | + | - | + | +/- | - | + | - | - | + |
| 18. Repeat interview | - | - | - | - | - | - | - | - | - | + |
| 19. Audio-visual recording | + | + | - | + | + | + | - | - | - | - |
| 20. Field notes | - | - | - | - | - | - | - | - | - | - |
| 21. Duration | - | + | - | - | - | - | - | + | - | + |
| 22. Data saturation | - | - | - | - | + | - | - | - | - | - |
| 23. Transcripts returned | - | - | - | - | - | - | - | - | - | - |
| 24. Number of data coders | - | + | - | - | - | - | - | - | - | - |
| 25. Description of coding three | - | - | - | - | - | - | - | - | - | - |
| 26. Derivation of themes | - | + | - | + | - | - | - | - | - | - |
| 27. Software | - | + | - | - | - | + | - | - | - | - |
| 28. Participant checking | - | - | + | - | - | - | - | - | - | - |
| 29. Quotations presented | + | + | - | + | +/- | - | - | + | + | +/- |
| 30. Data and findings consistent | + | + | +/- | + | + | + | - | + | + | + |
| 31. Clarity of major themes | + | + | - | + | + | + | - | - | - | - |
| 32. Clarify of minor themes | + | + | - | + | + | - | - | - | - | - |
| Total + | 8.5 | 18 | 4 | 10.5 | 12 | 6 | 8.5 | 4.5 | 11 |

+ = criterion was properly described, one point was assigned; +/- = criterion was incompletely described, 0.5 points were assigned; - = criterion was not described, zero points were assigned.
References

1. Nap-van der Vlist, M.M.; van der Sprenkel, E.E.B.; Nijhof, L.N.; Grootenhuis, M.A.; van der Ent, C.K.; Swart, J.E.; van Royen-Kerkhof, A.; van Grotel, M.; van de Putte, E.M.; Nijhof, S.L.; et al. Daily Life Participation in Childhood Chronic Disease: A Qualitative Study on the Child’s and Parent’s Perspective. BMJ Paediatr. Open 2021, 5, e001057. [CrossRef] [PubMed]

2. Feudtner, C.; Rosenberg, A.R.; Boss, R.D.; Wiener, L.; Lyon, M.E.; Hinds, P.S.; Bluebond-Langner, M.; Wolfe, J. Challenges and Priorities for Pediatric Palliative Care Research Network Workshop. J. Pain Symptom Manag. 2019, 58, 909–917.e3. [CrossRef] [PubMed]

3. Hinds, P.S.; Menard, J.C.; Jacobs, S.S. The Child’s Voice in Pediatric Palliative and End-of-Life Care. Prog. Palliat. Care 2012, 20, 337–342. [CrossRef]

4. Hein, I.M.; Troost, P.W.; Broersma, A.; de Vries, M.C.; Daams, J.G.; Lindauer, R.J.L. Why Is It Hard to Make Progress in Assessing Children’s Decision-Making Competence? BMC Med. Ethics 2015, 16, 1. [CrossRef]

5. Fahner, J.C.; Rietjens, J.A.C.; Heide, A.; Delden, J.J.M.; Kars, M.C. Survey of Paediatricians Caring for Children with Life-limiting Conditions Found That They Were Involved in Advance Care Planning. Acta Paediatr. 2020, 109, 1011–1018. [CrossRef]

6. Durall, A.; Zurakowski, D.; Wolfe, J. Barriers to Conducting Advance Care Discussions for Children with Life-Threatening Conditions. Pediatrics 2012, 129, e975–e982. [CrossRef]

7. Sanderson, A.; Zurakowski, D.; Wolfe, J. Clinician Perspectives Regarding the Do-Not-Resuscitate Order. JAMA Pediatrics 2013, 167, 954–958. [CrossRef]

8. Feenstra, B.; Boland, L.; Lawson, M.L.; Harrison, D.; Kryworuchko, J.; Leblanc, M.; Stacey, D. Interventions to Support Children’s Engagement in Health-Related Decisions: A Systematic Review. BMC Pediatrics 2014, 14, 109. [CrossRef]

9. van Driessche, A.; de Vlemink, A.; Gilissen, J.; Kars, M.C.; van der Werf ten Bosch, J.; Deliens, L.; Cohen, J.; Beernaert, K. Advance Care Planning for Adolescents and Their Parents: Study Protocol of the BOOSTPACP Multi-Centre Randomised Controlled Trial and Process Evaluation. BMC Pediatrics 2021, 21, 376. [CrossRef]

10. Myers, J.; Cosby, R.; Gzik, D.; Harle, I.; Harrold, D.; Incardona, N.; Walton, T. Provider Tools for Advance Care Planning and Goals of Care Discussions: A Systematic Review. Am. J. Hosp. Palliat. Med. 2018, 35, 1123–1132. [CrossRef]

11. Fahner, J.C.; Rietjens, J.; van der Heide, A.; Milota, M.; van Delden, J.; Kars, M. Evaluation Showed That Stakeholders Valued the Support Provided by the Implementing Pediatric Advance Care Planning Toolkit. Acta Paediatr. Int. J. Paediatr. 2020, 110, 237–246. [CrossRef]

12. Fahner, J.C.; Beunders, A.J.M.; van der Heide, A.; Rietjens, J.A.C.; Vanderschuren, M.M.; van Delden, J.J.M.; Kars, M.C. Interventions Guiding Advance Care Planning Conversations: A Systematic Review. J. Am. Med. Dir. Assoc. 2018, 20, 227–248. [CrossRef]

13. Lotz, J.D.; Jox, R.J.; Borasio, G.D.; Führer, M. Pediatric Advance Care Planning: A Systematic Review. Pediatrics 2013, 131, e873–e880. [CrossRef]

14. Hughes, B.; O’Brien, M.R.; Flynn, A.; Knighting, K. The Engagement of Young People in Their Own Advance Care Planning Process: A Systematic Narrative Synthesis. Palliat. Med. 2018, 32, 1147–1166. [CrossRef]

15. Lotz, J.D.; Daxer, M.; Jox, R.J.; Borasio, G.D.; Führer, M. “Hope for the Best, Prepare for the Worst”: A Qualitative Interview Study on Parents’ Needs and Fears in Pediatric Advance Care Planning. Palliat. Med. 2017, 31, 764–771. [CrossRef]

16. Needle, J.S.; Peden-McAlpine, C.; Liaschenko, J.; Koschmann, K.; Sanders, N.; Smith, A.; Schellinger, S.E.; Lyon, M.E. “Can You Tell Me Why You Made That Choice?”: A Qualitative Study of the Influences on Treatment Decisions in Advance Care Planning among Adolescents and Young Adults Undergoing Bone Marrow Transplant. Palliat. Med. 2019, 34, 281–290. [CrossRef]

17. Wadsworth, B. Piaget’s Theory of Cognitive Development: An Introduction for Students of Psychology and Education; McKay: New York, NY, USA, 1971.

18. Coyne, I. Children’s Participation in Consultations and Decision-Making at Health Service Level: A Review of the Literature. Int. J. Nurs. Stud. 2008, 45, 1682–1689. [CrossRef]

19. Kars, M.C.; Grypdonck, M.H.F.; van Delden, J.J.M. Being a Parent of a Child with Cancer throughout the End-of-Life Course. Oncol. Nurs. Forum 2011, 38, E260–E271. [CrossRef]

20. Kars, M.C.; Grypdonck, M.H.F.; de Bock, L.C.; van Delden, J.J.M. The Parents’ Ability to Attend to the “Voice of Their Child” with Incurable Cancer during the Palliative Phase. Health Psychol. 2015, 34, 446–452. [CrossRef]

21. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097. [CrossRef]

22. Zwakman, M.; Verbene, L.M.; Kars, M.C.; Hooft, L.; van Delden, J.J.M.; Spijker, R. Introducing PALETTE: An Iterative Method for Conducting a Literature Search for a Review in Palliative Care. BMC Palliat. Care 2018, 17, 82. [CrossRef]

23. Ouzzani, M.; Hammad, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan—A Web and Mobile App for Systematic Reviews. Syst. Rev. 2016, 5, 210. [CrossRef]

24. Rietjens, J.A.C.; Sudore, R.L.; Connolly, M.; van Delden, J.J.; Drickamer, M.A.; Droger, M.; van der Heide, A.; Heyland, D.K.; Houttekier, D.; Janssen, D.J.A.; et al. Definition and Recommendations for Advance Care Planning: An International Consensus Supported by the European Association for Palliative Care. Lancet Oncol. 2017, 18, e543–e551. [CrossRef]

25. Schulz, R.; Czaia, S.J.; McKay, J.R.; Orly, M.G.; Belle, S.H. Intervention Taxonomy (ITAX): Describing Essential Features of Interventions. Am. J. Health Behav. 2010, 34, 811–821. [CrossRef]
26. Higgins, J.P.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions; Higgins, J.P., Green, S., Eds.; Version 5.1.0.; John Wiley and Sons: West Sussex, UK, 2011.
27. Tong, A.; Sainsbury, P.; Craig, J. Consolidated Criteria for Reporting Qualitative Research (COREQ): A 32-Item Checklist for Interviews and Focus Groups. *Int. J. Qual. Health Care* 2007, 19, 349-357. [CrossRef]
28. Dixon-Woods, M.; Sutton, A.; Shaw, R.; Miller, T.; Smith, J.; Young, B.; Bonas, S.; Booth, A.; Jones, D. Appraising Qualitative Research for Inclusion in Systematic Reviews: A Quantitative and Qualitative Comparison of Three Methods. *J. Health Serv. Res. Policy* 2007, 12, 42-47. [CrossRef]
29. Popay, J.; Roberts, H.; Sowden, A.; Petticrew, M. Guidance on the Conduct of Narrative Synthesis in Systematic Reviews: A Product from the ESRC Methods Programme; Version 1; Lancaster University: Lancaster, UK, 2006.
30. Dierckx de Casterlé, B.; Gastmans, C.; Bryon, E.; Denier, Y. QUAGOL: A Guide for Qualitative Data Analysis. *Int. J. Nurs. Stud.* 2012, 49, 360-371. [CrossRef]
31. Dallas, R.H.; Kimmel, A.; Wilkins, M.L.; Rana, S.; Garcia, A.; Cheng, Y.I.; Wang, J.; Lyon, M.E. Acceptability of Family-Centered Advanced Care Planning for Adolescents with HIV. *Pediatrics* 2016, 138, e20161854. [CrossRef] [PubMed]
32. Lyon, M.E.; Garvie, P.A.; Briggs, L.; He, J.; McCarter, R.; D’Angelo, L.J. Development, Feasibility, and Acceptability of the Family/Adolescent-Centered Advance Care Planning Intervention for Adolescents with HIV. *J. Palliat. Med.* 2009, 12, 363-372. [CrossRef] [PubMed]
33. Lyon, M.E.; Garvie, P.A.; McCarter, R.; Briggs, L.; He, J.; D’Angelo, L.J. Who Will Speak for Me? Improving End-of-Life Decision-Making for Adolescents with HIV and Their Families. *Pediatrics* 2009, 123, e199-e206. [CrossRef] [PubMed]
34. Lyon, M.E.; Garvie, P.A.; Briggs, L.; He, J.; Malow, R.; D’angelo, L.J.; McCarter, R. Is It Safe? Talking to Teens with HIV/AIDS about Death and Dying: A 3-Month Evaluation of Family Centered Advance Care (FACE) Planning-Anxiety, Depression, Quality of Life. *Dove Press J.* 2010, 2, 27-37. [CrossRef]
35. Lyon, M.E.; Jacobs, S.; Briggs, L.; Cheng, Y.I.; Wang, J. Family-Centered Advance Care Planning for Teens with Cancer. *JAMA Pediatrics* 2013, 167, 460-467. [CrossRef]
36. Lyon, M.E.; Jacobs, S.; Briggs, L.; Cheng, Y.I.; Wang, J. A Longitudinal, Randomized, Controlled Trial of Advance Care Planning for Teens with Cancer: Anxiety, Depression, Quality of Life, Advance Directives, Spirituality. *J. Adolesc. Health* 2014, 54, 710-717. [CrossRef]
37. Hays, R.M.; Valentine, J.; Haynes, G.; Russell Geyer, J.; Villareale, N.; Mckinstry, B.; Varni, J.W.; Churchill, S.S. The Seattle Pediatric Palliative Care Project: Effects on Family Satisfaction and Health-Related Quality of Life. *J. Palliat. Med.* 2006, 9, 716-728. [CrossRef]
38. Hendricks-Ferguson, V.L.; Pradhan, K.; Shih, C.S.; Gauvain, K.M.; Kane, J.R.; Liu, J.; Haase, J.E. Pilot Evaluation of a Palliative and End-of-Life Communication Intervention for Parents of Children with a Brain Tumor. *J. Pediatric Oncol. Nurs.* 2017, 34, 203-213. [CrossRef]
39. Jacobs, S.; Perez, J.; Cheng, Y.I.; Sill, A.; Wang, J.; Lyon, M.E. Adolescent End of Life Preferences and Congruence with Their Parents’ Preferences: Results of a Survey of Adolescents with Cancer. *Pediatric Blood Cancer* 2015, 62, 710-714. [CrossRef]
40. Kazmerski, T.M.; Weiner, D.J.; Matisko, J.; Schachner, D.; Lerch, W.; May, C.; Maurer, S.H. Advance Care Planning in Adolescents and Young Adults: A Systematic Review of the Literature. *Pediatrics* 2018, 133, 1304-1310. [CrossRef]
41. Moody, K.M.; Hendricks-Ferguson, V.L.; Baker, R.; Perkins, S.; Haase, J.E. A Pilot Study of the Effects of COMPLETE: A Communication Plan Early Through End of Life, on End-of-Life Outcomes in Children with Cancer. *J. Pain Symptom Manag.* 2020, 60, 417-421. [CrossRef]
42. Friebert, S.; Grosseohme, D.H.; Baker, J.N.; Needle, J.; Thompkins, J.D.; Cheng, Y.I.; Wang, J.; Lyon, M.E. Congruence Gaps Between Adolescents with Cancer and Their Families Regarding Values, Goals, and Beliefs About End-of-Life Care. *JAMA Netw Open* 2020, 3, e205424. [CrossRef]
43. Feraco, A.M.; Brand, S.R.; Gagne, J.; Sullivan, A.; Block, S.D.; Wolfe, J. Development of the “Day 100 Talk”: Addressing Existing Communication Gaps during the Early Cancer Treatment Period in Childhood Cancer. *Pediatric Blood Cancer* 2018, 65, e269-e272. [CrossRef]
44. Hartley, G.; Berger, Z.; Maynard, L. The Development and Evaluation of a Holistic Needs Assessment within Children’s Palliative Care. *Int. J. Palliat. Nurs.* 2016, 22, 236-242. [CrossRef]
45. Finlay, F.; Lewis, M.; Lenton, S.; Poon, M. Planning for the End of Children’s Lives -the Lifetime Framework. *Child: Care Health Dev.* 2008, 34, 542-544. [CrossRef]
46. Kline, C.; Reineke, A.; Auger, J.A.; Willert, J.; Roberts, W.; Schielf, D. Effects of a Unique Pediatric Hematology-Oncology Palliative Care Program on Medical Decision-Making and Communication between Healthcare Providers and Families: Results of a Supportive Care Survey. *Prog. Palliat. Care* 2012, 20, 13-18. [CrossRef]
47. Lyon, M.E.; Thompkins, J.D.; Fratantoni, K.; Fraser, J.L.; Schellinger, S.E.; Briggs, L.; Friebert, S.; Aoun, S.; Cheng, Y.I.; Wang, J. Family Caregivers of Children with Rare Diseases: A Novel Palliative Care Intervention. *BMJ Supportive Palliat. Care* 2019, 1-10. [CrossRef]
48. Wiener, L.; Zadeh, S.; Battles, H.; Baird, K.; Ballard, E.; Osherow, J.; Pao, M. Allowing Adolescents and Young Adults to Plan Their End-of-Life Care. *Pediatrics* 2012, 130, 897-905. [CrossRef]
49. Wiener, L.; Ballard, E.; Brennan, T.; Battles, H.; Martinez, P.; Pao, M. How i Wish to Be Remembered: The Use of an Advance Care Planning Document in Adolescent and Young Adult Populations. *J. Palliat. Med.* 2008, 11, 1309-1313. [CrossRef]
50. Noyes, J.; Hastings, R.P.; Lewis, M.; Hain, R.; Bennett, V.; Hobson, L.; Spencer, L.H. Planning Ahead with Children with Life-Limiting Conditions and Their Families: Development, Implementation and Evaluation of ‘My Choices’. BMC Palliat. Care 2013, 12, 5. [CrossRef]
51. Christenson, K.; Lybrand, S.A.; Hubbard, C.R.; Hubble, R.A.; Absens, L.; Black, P. Including the Perspective of the Adolescent in Palliative Care Preferences. J. Pediatric Health Care 2010, 24, 286–291. [CrossRef]
52. Curtin, K.B.; Watson, A.E.; Wang, J.; Okonkwo, O.C.; Lyon, M.E. Pediatric Advance Care Planning (PACP) for Teens with Cancer and Their Families: Design of a Dyadic, Longitudinal RCTT. Contemp. Clin. Trials 2017, 62, 121–129. [CrossRef]
53. Dallas, R.H.; Wilkins, M.L.; Wang, J.; Garcia, A.; Lyon, M.E. Longitudinal Pediatric Palliative Care: Quality of Life & Spiritual Struggle (FACE): Design and Methods. Contemp. Clin. Trials 2012, 33, 1033–1043. [CrossRef]
54. Fraser, J.; Harris, N.; Berringer, A.J.; Prescott, H.; Finlay, F. Advanced Care Planning in Children with Life-Limiting Conditions-The Wishes Document. Arch. Dis. Child. 2010, 95, 79–82. [CrossRef] [PubMed]
55. Gallagher, A.; Peacock, M.; Arber, A. Helping Young People Who Have Learning Disabilities and Their Families to Plan End of Life Care: The ADVANCE Toolkit. Learn. Disabil. Pract. 2018, 21, 33. [CrossRef] [PubMed]
56. Zadeh, S.; Pao, M.; Wiener, L. Opening End-of-Life Discussions: How to Introduce Voicing My CHOICES™, an Advance Care Planning Guide for Adolescents and Young Adults. Palliat. Supportive Care 2015, 13, 591–599. [CrossRef] [PubMed]
57. van Breemen, C.; Johnston, J.; Carwana, M.; Louie, P. Serious Illness Conversations in Pediatrics: A Case Review. Children 2020, 7, 102. [CrossRef]
58. Baker, J.N.; Hinds, P.S.; Spunt, S.L.; Barfield, R.C.; Allen, C.; Powell, B.C.; Anderson, L.H.; Kane, J.R. Integration of Palliative Care into the Ongoing Care of Children with Cancer: Individualized Care Planning and Coordination. Pediatric Clin. N. Am. 2008, 55, 223–250. [CrossRef]
59. Snaman, J.M.; Blazin, L.; Holder, R.L.; Wolfe, J.; Baker, J.N. Identifying and Quantifying Adolescent and Young Adult Patient Preferences in Cancer Care: Development of a Conjoint Analysis-Based Decision-Making Tool. J. Adolesc. Young Adult Oncol. 2019, 8, 212–216. [CrossRef]
60. Toce, S.; Collins, M.A. The FOOTPRINTS SM Model of Pediatric Palliative Care. J. Palliat. Med. 2003, 6, 989–1000. [CrossRef]
61. Feyer, D.R. Care of the Dying Adolescent: Special Considerations. Pediatrics 2004, 113, 381–388. [CrossRef]
62. Longbottom, S.; Slaughter, V. Sources of Children’s Knowledge about Death and Dying. Philos. Trans. R. Soc. B Biol. Sci. 2018, 373, 20170267. [CrossRef]
63. Shaffer, D.; Kipp, K. Developmental Psychology; Thomson Wadsworth: Belmont, NSW, Australia, 2007.
64. Reed, J.; Warner-Rogers, J. Child Neuropsychology; Concept, Theory and Practice; Reed, J., Warner-rogers, J., Eds.; Wiley-Blackwell: Oxford, UK, 2008.
65. Rueda, M.R.; Fan, J.; McCandliss, B.D.; Halperin, J.D.; Gruber, D.B.; Lercari, L.P.; Posner, M.I. Development of Attentional Networks in Childhood. Neuropsychologia 2004, 42, 1029–1040. [CrossRef]
66. Waszak, F.; Li, S.-C.; Hommel, B. The Development of Attentional Networks: Cross-Sectional Findings from a Life Span Sample. Dev. Psychol. 2010, 46, 337–349. [CrossRef]
67. Guillery-Girard, B.; Martins, S.; Deshayes, S.; Hertz-Pannier, L.; Chiron, C.; Jambaque, I.; Landeau, B.; Clochon, P.; Chételat, G.; Eustache, F. Developmental Trajectories of Associative Memory from Childhood to Adulthood: A Behavioral and Neuroimaging Study. Front. Behav. Neurosci. 2013, 7, 126. [CrossRef]
68. Thaler, N.S.; Goldstein, G.; Pettigrew, J.W.; Luther, J.F.; Reynolds, C.R.; Allen, D.N. Developmental Aspects of Working and Associative Memory. Arch. Clin. Neuropsychol. 2013, 28, 348–355. [CrossRef]
69. Rhodes, S.M.; Murphy, D.; Hancock, P.J.B. Developmental Changes in the Engagement of Episodic Retrieval Processes and Their Relationship with Working Memory during the Period of Middle Childhood. Br. J. Dev. Psychol. 2011, 29, 865–882. [CrossRef]
70. Sprendel, V.; Kipp, K.H.; Mecklinger, A. Developmental Changes in Item and Source Memory: Evidence From an ERP Recognition Memory Study with Children, Adolescents, and Adults. Child Dev. 2011, 82, 1638–1953. [CrossRef]
71. Czernochowski, D.; Mecklinger, A.; Johansson, M. Age-Related Changes in the Control of Episodic Retrieval: An ERP Study of Recognition Memory in Children and Adults. Dev. Sci. 2009, 12, 1026–1040. [CrossRef]
72. Cotton, C.R.; Range, L. Children’s Death Concepts: Relationship to Cognitive Functioning, Age, Experience with Death, Fear of Death, and Hopelessness. J. Clin. Child Adolesc. Psychol. 1990, 19, 123–127. [CrossRef]
73. Hunter, S.B.; Smith, D.E. Predictors of Children’s Understandings of Death: Age, Cognitive Ability, Death Experience and Maternal Communicative Competence. OMEGA-J. Death Dying 2008, 57, 143–162. [CrossRef] [PubMed]
74. Rosengren, K.S.; Gutierrez, I.T.; Schein, S.S., IV. COGNITIVE DIMENSIONS OF DEATH IN CONTEXT. Monogr. Soc. Res. Child Dev. 2014, 79, 62–82. [CrossRef] [PubMed]
79. Slaughter, V. Young Children’s Understanding of Death. *Aust. Psychol.* 2005, 40, 179–186. [CrossRef]
80. Slaughter, V.; Lyons, M. Learning about Life and Death in Early Childhood. *Cogn. Psychol.* 2003, 46, 1–30. [CrossRef]
81. Waxman, S.; Medin, D. Experience and Cultural Models Matter: Placing Firm Limits on Childhood Anthropocentrism. *Hum. Dev.* 2007, 50, 23–30. [CrossRef]
82. Markovits, H. The Development of Abstract Conditional Reasoning; Barrouillet, P.; Gauffroy, C., Eds.; Psychology Press: London, UK, 2013.
83. Pillow, B.H.; Pearson, R.M.; Hecht, M.; Bremer, A. Children’s and Adults’ Judgments of the Certainty of Deductive Inferences, Inductive Inferences, and Guesses. *J. Genet. Psychol.* 2010, 171, 203–217. [CrossRef]
84. Grisso, T.; Appelbaum, P.S.; Hill-Fotouhi, C. The MacCAT-T: A Clinical Tool to Assess Patients’ Capacities to Make Treatment Decisions. *Psychiatr. Serv.* 1997, 48, 1415–1419. [CrossRef]
85. Frith, U.; Frith, C.D. Development and Neurophysiology of Mentalizing. *Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci.* 2003, 358, 459–473. [CrossRef]
86. Abu-Akel, A. A Neurobiological Mapping of Theory of Mind. *Brain Res. Rev.* 2003, 43, 29–40. [CrossRef]
87. Christensen, T. Sick Girl Speaks. In *Sick Girl Speaks*; Christensen, T., Ed.; iUniverse: New York, NY, USA, 2007.
88. Blakemore, S.-J.; Mills, K.L. Is Adolescence a Sensitive Period for Sociocultural Processing? *Annu. Rev. Psychol.* 2014, 65, 187–207. [CrossRef]
89. Casey, B.J.; Jones, R.M.; Hare, T.A. The Adolescent Brain. *Ann. N. Y. Acad. Sci. USA* 2008, 1124, 111–126. [CrossRef]
90. Giesbertz, N.A.A.; Bredenoord, A.L.; van Delden, J.J.M. Clarifying Assent in Pediatric Research. *Eur. J. Hum. Genet.* 2014, 22, 266–269. [CrossRef]
91. National Institutes of Health Children’s Assent to Clinical Trial Participation. Online Resource from National Cancer Institute. Available online: https://www.cancer.gov/about-cancer/treatment/clinical-trials/patient-safety/childrens-assent (accessed on 10 April 2022).
92. Feudtner, C.; Kang, T.I.; Hexem, K.R.; Friedrichsdorf, S.J.; Osenga, K.; Siden, H.; Friebert, S.E.; Hays, R.M.; Dussel, V.; Wolfe, J. Pediatric Palliative Care Patients: A Prospective Multicenter Cohort Study. *Pediatrics* 2011, 127, 1094–1101. [CrossRef]
93. Shehata, G.A. Childhood Cognitive Impairment. *Acta Psychopathol.* 2016, 02, 37. [CrossRef]
94. Ferraz de Arruda-Colli, M.N.; Sansom-Daly, U.; dos Santos, M.A.; Wiener, L. Considerations for the Cross-Cultural Adaptation of an Advance Care Planning Guide for Youth with Cancer. *Clin. Pract. Pediatric Psychol.* 2018, 6, 341–354. [CrossRef]
95. Huang, C.-Y. How Culture Influences Children’s Development. Online Resource from the Conversation. Available online: https://theconversation.com/how-culture-influences-childrens-development-99791 (accessed on 8 April 2022).
96. Jaakkola, R.O.; Slaughter, V. Children’s Body Knowledge: Understanding ‘Life’ as a Biological Goal. *Br. J. Dev. Psychol.* 2002, 20, 325–342. [CrossRef]
97. Piers, R.; Albers, G.; Gilissen, J.; de Lepelere, J.; Steyaert, J.; van Mechelen, W.; Steeman, E.; Dillen, L.; vanden Berghe, P.; van den Block, L. Advance Care Planning in Dementia: Recommendations for Healthcare Professionals. *BMC Palliat. Care* 2018, 17, 88. [CrossRef]
98. Robinson, L.; Tang, E.; Taylor, J.-P. Dementia: Timely Diagnosis and Early Intervention. *BMJ* 2015, 350, h3029. [CrossRef]
99. Hegde, S.; Ellajosyula, R. Capacity Issues and Decision-Making in Dementia. *Ann. Indian Acad. Neurol.* 2016, 19, 34–39. [CrossRef]